Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library

School of Medicine

2005

Optimal management of Melanoma in situ and
Stage I melanoma
Nicholas Brittain Countryman
Yale University

Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
Recommended Citation
Countryman, Nicholas Brittain, "Optimal management of Melanoma in situ and Stage I melanoma" (2005). Yale Medicine Thesis
Digital Library. 2492.
http://elischolar.library.yale.edu/ymtdl/2492

This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

CUSHING/WHITNEY
MEDICAL LIBRARY

Permission to photocopy or microfilm processing
of this thesis for the purpose of individual
scholarly consultation or reference is hereby
granted by the author. This permission is not to
be interpreted as affecting publication of this work
or otherwise placing it in the public domain, and
the author reserves all rights of ownership
guaranteed under common law protection of
unpublished manuscripts'.

,

Date

Digitized by the Internet Archive
in 2017 with funding from
The National Endowment for the Humanities and the Arcadia Fund

https://archive.org/details/optimalmanagemenOOcoun

Optimal Management of Melanoma in situ
and Stage I Melanoma:
A Retrospective Case Review

A Thesis Submitted to the
Yale University School of Medicine
In Partial Fulfillment of the Requirements for the
Degree of Doctor of Medicine

by
Nicholas Brittain Countryman
2005

YALE MEDICAL LIBRARY

iAUG 1 0 2005

TO

13

-hYfc
TO

Abstract
The incidence of cutaneous melanoma is on the rise. While a significant amount
of work has been done to evaluate the importance of various demographic, pathologic
and clinical information in patients with melanoma in situ and stage I melanoma, no
study to our knowledge has comprehensively evaluated this information. In this paper,
we performed a retrospective case review of the outpatient management of 208 lesions of
melanoma in situ and stage I melanoma during the years of 1988-2005. This included
137 melanoma in situ lesions and 71 stage I melanoma lesions. We sought to evaluate
this continuum of early melanoma because we deemed these to be the vast majority of
melanoma lesions presenting to dermatologic surgery centers while realizing that these
two categories present two unique entities. 53.85% of the lesions were present in male
patients while 46.15% of the lesions were diagnosed in female patients. The mean age of
the entire patient population is 65.57 years. The mean age of patients that presented with
malignant melanoma, superficial spreading is 63.94 years, while the mean age of the
patient population with melanoma in situ is 66.67 years. The mean age of males is 68.34
years. The mean age of females is 65.5 1 years. Of the lesions in males, 37.50% are
malignant melanoma while the remaining 62.50%> are melanoma in situ. Of the lesions
on females, 30.21% are malignant melanoma while 69.79% were diagnosed as melanoma
in situ. Overall, the mean lesion size was 13.90 mm in diameter. The mean size of all of
the melanoma in situ lesions is 14.50 mm, while the mean size of all lesions diagnosed as
malignant melanoma is 1 1.68 mm. The mean depth of the malignant melanoma lesions is
0.42 mm.
From our data, stage I melanoma, melanoma in situ, and all lesions considered in
aggregate show a statistically significant predilection to the head and neck areas.
Additionally, when comparing stage I melanoma to melanoma in situ, the former lesions
show a significant propensity for the trunk. Additionally, melanoma in situ lesions of the
trunk showed a significant propensity for the right side. Our data demonstrates a low
local recurrence rate of 4.38% for melanoma in situ lesions and a 1.41%’ local recurrence
rate for stage 1 lesions. Our data indicates that all of the local recurrence occurred on the
head and neck. Analysis suggests that lesions of the head and neck are more likely to
recur than lesions elsewhere on the body. Further analysis did not suggest a difference of
local recurrence rates between those patients treated with currently recommended clinical
surgical margins of 5 mm in melanoma in site and l cm in stage I melanoma. All
recurrences in our study occurred in patients treated with the recommended surgical
margins. Finally, lesions of the head and neck were more likely to be melanoma in situ
lesions than stage I melanoma in a statistically significant fashion.
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Introduction
The incidence of melanoma of the skin has rapidly risen (1). An estimated 59,580
new cases of invasive melanoma of the skin will occur in 2005 resulting in approximately
7,700 deaths. Additionally, another 46,170 new cases of melanoma in situ are expected
in 2005 (1). At times progressive and deadly, melanoma is a disease of both the young
and old. Melanoma is one of the most serious cancers when measured by years of life
lost (2). Fortunately today, due to early detection and aggressive treatment, the majority
of patients presents with localized disease that is limited to the skin (3) which decreases
the mortality rate from melanoma. Increased awareness due to preventive skin cancer
education programs has led to the presentation of melanoma at younger ages and earlier
stages of disease (4, 5).
In the current staging system for melanoma, the American Joint Committee on
Cancer (AJCC) classifies lesions based on tumor thickness (6). This staging system is
classified by thresholds that correlate with clinical management and prognosis of
melanoma patients. The AJCC designates stage I as tumors less than 1.0 mm thickness,
stage II between 1.01-2.0 mm thickness, stage III between 2.01-4.0 mm thickness, and
stage IV greater than 4.0 mm thickness. According to an AJCC study, tumor thickness
was the most powerful independent prognostic factor for patients with primary cutaneous
melanoma (6). Early melanoma includes melanoma in situ and invasive lesions less than
1.0 mm in depth (7).
Detection and treatment of melanoma at its earliest stages is usually curative.
Detection of melanoma at later stages often leads to significant morbidity and mortality
(8). Local surgical treatment of early melanoma remains the standard of care, but the

technique used, especially in relation to the clinical surgical margins remains an area of
ongoing debate in current literature. The earliest reports by Samson Handley in 1905
suggested the need for the removal of 2 inches of subcutaneous tissue down to the fascia
for melanoma (9). In 1962, Petersen, et al. suggested the need for up to 5 cm margins of
normal skin even for thin invasive melanoma (10). These aggressive approaches were
based on their belief that these treatments were necessary to prevent local recurrences and
metastatic disease. Currently, most physicians follow the National Institutes of Health
recommendation of 5 mm of clear clinical margins for melanoma in situ and 10 mm of
clear clinical margins for stage I melanoma (7). In the case of melanoma in situ, local
excision results in a 99% disease-free, long-term survival with local recurrence
accounting for the other 1%. In the case of thin invasive melanoma, surgical removal
results in greater than 90% disease-free, long-term survival (7).
Obtaining standard surgical margins in the treatment of early melanoma is not
always practical. Often patients of advanced age or patients with lesions in cosmetically
difficult areas require the use of narrower clinical margins or alternative therapies.
Imiquimod, cryotherapy, and Q-switched ruby laser have all been suggested as
alternatives to surgical treatment especially in patients of advanced age with melanoma in
situ. Additionally, the use of clinical margins less than those previously suggested as the

standard of care, especially in cosmetically sensitive areas such as the face, have been
used with varying success (1 1-13). Although most physicians agree that obtaining 5 mm
and 10 mm clinical margins for melanoma in situ and thin invasive melanoma
respectively is optimal, significant exploration around the use of smaller margins
continues. Although a number of researchers have evaluated the use of narrow margins
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for intermediate invasive melanoma (13-15), few have examined the use of narrow
margins in melanoma in situ and early invasive melanoma (12). Further research is
needed to evaluate the use of narrow margins because the current evidence is not
sufficient to address optimal surgical margins especially in the case of early melanoma.
The importance of cure at the time of initial treatment is due to the fact that local
recurrence of melanoma may lead to considerably worse prognosis (16. 17). Some
studies have suggested an association between narrow excision margins and recurrence
rates (17). Reports of the rate of local recurrence of all melanomas even melanoma in
situ vary dramatically from 0-50% within 5 years (18-20). One recent article reported a

6.8% 5-year recurrence rate for surgically removed melanoma in situ lesions. Further,
this study suggested that treatment other than excision as well as site of involvement were
significant prognostic variables in relation to recurrence. Patient age at treatment was not
found to be a significant variable in this study (20).
In addition to the dehate regarding surgical margins in melanoma, the optimal
excision technique employed for the removal of early melanoma remains controversial.
Some physicians suggest the use of Mohs’ micrographic surgery (21, 22). though the use
of frozen sections for evaluation of disease-free margins remains controversial. Staged
excision procedures using permanent sections are often employed for the treatment of
melanoma (23). This technique employs serial sections when necessary to spare tissue
while ensuring the removal of the entire lesion.
Because of the lack of definitive guidelines regarding the optimal management of
early stage melanoma, we reviewed a range of established clinical parameters to clarify
better the useful treatment approaches for early melanoma. Our review that follows
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presents one of the most complete and thorough reviews of treatment and pathological
criteria of melanoma in situ and stage 1 melanoma.

Specific Aims and Hypotheses
Aims

1) To define practical clinical parameters for the treatment of early melanoma including
clinical margins.
2) To evaluate predictors of recurrence of early melanoma.

Hypotheses:

1) Age, sex, body site, and treatment modalities used in the treatment of melanoma
affect the recurrence rate.
2) However, “suboptimal” margins do not affect recurrence rates; therefore current
recommendations of 5 millimeters for melanoma in situ and 10 millimeters for stage
melanoma need not he absolute guidelines under certain circumstances especially in
cosmetically sensitive areas and in patients with advance age.

Methods
We performed a retrospective case review of the outpatient management of
melanoma in situ and stage I melanoma at Yale Dermatologic Surgery and Cutaneous
Oncology Section in the Department of Dermatology. The study period was 1988-2005.
The study was approved under Human Investigation Committee protocol # 27327. In
order to define our patient population, we performed a search of all pathological
specimens for any diagnosis including melanoma. All patients with the diagnosis of
melanoma in situ and stage I melanoma, superficial spreading type with a depth less than
1.0 mm were included in the study. In patients with multiple primary lesions, each lesion
was treated as a separate individual case.
Patients who presented with stage I melanoma, superficial spreading type with a
depth greater than 1.0 mm were excluded. Likewise, patients with stage I melanoma,
acral lentiginous type and nodular type were excluded because they represent unique
diagnostic and treatment entities. Also excluded from statistical analysis were all patients
treated with non-surgical methods including imiquimod and Q-switched Ruby Laser.
These excluded patients are discussed anecdotally in the results and discussion sections.
Patients that were definitively treated by other providers who were referred as local
recurrences were likewise excluded. Additionally, patients with metastatic disease at
presentation were excluded. Patients who were not definitively treated at our clinic
including those who presented for consultation only or those patients who were referred
to other physicians for definitive treatment and often sentinel node biopsy were likewise
excluded. Although rare, patients with incomplete or unavailable charts were excluded.
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All data was recorded in a Microsoft Excel 2002 spreadsheet under human
investigation committee protocol and all data was analyzed using the chi-square test in
SAS program (SAS Institute Inc. SAS Release 8.2. Cary, NC; 2001) unless otherwise
indicated. Margin data was recorded from the operative report and added to the margins
of the previous stage(s) of excision if multiple stages were taken. In the rare case in
which data about the clinical surgical margins or clinical size of lesion was not recorded
in the patient chart, these values were calculated using the measurements of the
pathological specimen with the assumption that specimens shrink approximately 30
percent from their in vivo state. In the case when clinical margins were not recorded, the
width of the ellipse or the diameter of the circle of the pathological specimen was
multiplied by 1.3 and the larger diameter of the lesion was subtracted to approximate thee
clinical margin. Conversely, if the clinical size of the lesion was not recorded, then the
width of the ellipse or the diameter of the circle of the pathological specimen was
multiplied by 1.3 and then the recorded clinical margin was subtracted from the
calculated value to obtain the approximate diameter of the lesion (see figure 1).
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Results
Inclusion & Exclusion
A total of 275 patients were identified using the study criteria. A total of 77
patients were excluded (see Table 1). The charts of 14 patients were either incomplete or
unavailable. 3 patients with malignant melanoma, acral lentiginous type and 2 with
nodular type were excluded. A total of 14 patients were treated with non-surgical
modalities including 10 treated with imiquimod and 4 treated with Q-switched ruby laser.
Of note, 7 of the 10 patients that were treated with imiquimod have been followed
clinically without any indication of recurrent melanoma in situ. Three patients presented
with local recurrences. Two patients treated with the laser therapy required further
excision while the other 2 required no further treatment.
Melanoma in situ lesions on three patients proved extremely difficult to remove
completely; alter multiple stages with positive margins, the decision was made to follow
these lesions clinically. Other excluded patients include: 21 patients who were referred
to other physicians for definitive treatment and sentinel node biopsy; 2 patients that
presented for consultation only; 4 patients who presented with local recurrence; and 4
patients who presented with metastatic disease. Finally, 10 patients with stage I
melanoma, superficial spreading type were excluded with lesions between 1.0 mm and
2.9 mm in depth. Of note, our charts including outside consultation notes on these
patients indicated that none of the 10 patients excluded based on depth of lesion
experienced recurrence.
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A total of 198 patients with 208 primary lesions were evaluated in the statistical
analysis that follows (2 patients were treated for 2 primary lesions and 2 patients were
treated for 3 primary lesions).

Patient Demographics

112 (53.85%) of the lesions were present on male patients while 96 (46.15%) of
the lesions were present on female patients. The mean age of the entire patient
population was 65.57 +/- 14.43 years. The mean age of patients that presented with stage
I melanoma, superficial spreading was 63.94 +/- 16.76 years, while the mean age of the
patient population with melanoma in situ is 66.67 +/- 12.78 years. The mean age of
males was 68.34 +/- 13.08 years. The mean age of females was 65.5 1 +/- 15.00 years.
The mean time since treatment was 6.78 +/- 4.17 years in the entire patient population
with a median of 6.67 years. The range was 2.5 months to 14 years.

Description of Lesions Rased on Diagnosis

In the entire patient population, 71 (34.13%) of the lesions were stage I melanoma
while the remaining 137 (65.87%) were melanoma in situ. Of the lesions on males, 42
(37.50%) were stage I melanoma while the remaining 70 (62.50%) are melanoma in situ.
Of the lesions on females, 29 (30.21%) were stage I melanoma while 67 (69.79%) were
diagnosed as melanoma in situ.

Description of Lesions Rased on Size and Depth

In order to evaluate the size of the lesion, the greatest clinical measurement was
used. Overall, the mean lesion size was 13.90 +/- 8.62 mm in diameter. The mean size
of all of the melanoma in situ lesions was 14.50 +/- 8.84 mm, while the mean size of all
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lesions diagnosed as stage I melanoma was 1 1.68 +/- 7.02 mm. The mean depth of the
stage I melanoma lesions was 0.42 +/- 0.21 mm.

Description of Lesions Rased on Location

Table 2 illustrates the distribution of stage I melanoma and melanoma in situ by
body site and side. Body site is divided into 4 categories: head and neck (HN). upper
extremity (UE), trunk (T), and lower extremity (LE). Laterality is divided into left,
middle, and right. In Table 3 the lesions are further divided by diagnosis, body site
category, and side. Finally, in Table 4 the lesions of the trunk and head and neck are
separately divided into specific sites within the specific body site category. For the trunk
lesions, they are divided into front, back, and other (including shoulder and flank). For
the head and neck lesions, 10 separate subsets were employed: cheek, chin, ear, eyelid,
forehead, lip, neck, nose, scalp, and temple.

Pathologic Descriptors of Stage I Melanoma

Table 5 allocates the stage I melanoma lesions into categories based on
pathological criteria. These criteria include: the Clark's level, the presence or absence of
ulcerations, and the growth phase.

Recurrences

The overall local recurrence rate observed in our study population was 3.37%
with a 4.38% local recurrence rate for melanoma in situ lesion and a 1.41 % local
recurrence rate for stage 1 melanoma. We are not aware of any metastatic disease
occurring in our patient population. In our entire study population including melanoma
in situ and stage I melanoma, there was an overall 4.17% recurrence rate among female

patients and a 2.68% recurrence rate among male patients. Similarly, 4.27% of the
lesions on patients older than the mean age recurred while only 2.68% of the lesions on
patients younger than the mean recurred. All local recurrences arose on the head and
neck. The overall recurrence rate on the head and neck was 5.88% (6.81% for melanoma
in situ, 3.22% for stage I melanoma). Finally, 4.65% of lesions larger than the mean size

when measured hy greatest clinical diameter recurred while only 2.46% of lesions
smaller than the mean size recurred locally. All of this data along with corresponding
statistical values are reported in Table 6. The corresponding values from statistical
analysis of potential predictors of recurrence are included in this table.

Recurrences based on Margins

Margins of 2-10 mm were required to remove the melanoma in situ lesions with a
mean of 5.15 mm and a standard deviation of 1.60 mm. Margins of 3-20 mm were
employed to eradicate the stage 1 melanoma lesions with a mean of 9.11 mm and a
standard deviation of 3.00 mm. A vast majority of both sets of lesions were removed
successfully using the recommended 5 mm for melanoma in situ and 1 cm for stage I
melanoma. Under certain circumstances, narrower margins were employed, while in
other cases, larger clinical margins were necessary after repeated stages to remove the
entire lesion. The exact margins and number of cases that employ each respective margin
are reported in Table 7.

Recurrences based on Stages and Margins

Table 8 shows recurrences based on the number of stages necessary to remove the
lesion. For most lesions, only one stage was required to eradicate all disease although up

to five stages were required for one case of melanoma in situ. All local recurrences of
melanoma in situ and stage I melanoma occurred in excisions with a single stage.

Non-Surgical Treatment of Melanoma In Situ

As noted previously, 10 lesions were treated with imiquimod while 4 patients
were treated with Q-switched Ruby laser. Seven of the 10 patients treated with
imiquimod showed pathological clearance. During our study period, 3 of the 10 or 30%
of patients presented with local recurrences. Of the 4 patients treated with Q-switched
Ruby laser, 2 cleared clinically while 2 required further excision.

Diagnosis Data

In order to evaluate the impact of sex, age, body site, and lesion size on the
diagnosis of melanoma in situ or stage I melanoma, the number of stage I melanoma
patients in relation to each of these parameters was recorded as seen in Table 9. 30.21%
of female patients versus 37.50% of male patients in our patient population were
diagnosed with stage I melanoma. 38.10% of patients older than the mean age of our
population were diagnosed with stage I melanoma versus 31.45% in patients younger
than the mean population. Only 26.05% of the lesions of the head and neck were stage I
melanoma versus 44.94% of the lesions diagnosed on the remainder of the body. When
lesion size was considered, 37.70% of the lesions larger than the mean size were stage I
melanoma while 57.38% of lesions smaller than the mean size were stage I melanoma.

Evaluating Trends

Using data from Table 10, we evaluated potential trends in the depth and size of
lesions as well as patient age and sex over three consecutive five year periods. In order to
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increase the number of lesions for evaluation and statistical power of the analysis, our
entire spectrum of early melanoma including melanoma in situ lesions as well as stage 1
were combined. Corresponding statistical values are included for each analysis performed
with the data in Table 10.
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Discussion
Based on the recent literature as noted in our introduction, this work presents one
of the most complete and comprehensive case reviews of patients with melanoma in situ
and stage I melanoma. Most previous work focuses on just one of the many clinical
parameters that we evaluated in our study. The authors realize that one major
shortcoming of some of our analysis is that the cases of melanoma in situ were combined
with stage I melanoma cases. Previous studies and reviews have evaluated these two
entities as early melanoma (24). Although these two entities have very different
biologies, especially in regards to the metastatic potential of stage I melanoma (25), local
surgical treatment with narrow margins remains the widely accepted standard of care for
both processes. Furthermore, these entities represent a majority of melanoma treated by
dermatologic surgeons. In order to account for the differences between melanoma in situ
and stage I melanoma, when possible, analysis was done on the two groups separately
and aggregately.
The average time since treatment records only a gross estimate of disease-free
survival in these patients. When noted in chart, date of death was taken into account
when calculating time since treatment. Patients have not yet been contacted for follow¬
up, and most likely we are unaware of some patients who are now deceased. We also are
aware that some patients may have been treated at other institutions, though none of the
patients analyzed in this section submitted a request for transfer of their medical records.
Closer follow-up via phone calls and examination will give a better measure of diseasefree survival.
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Patient Demographics

The larger proportion of male patients (53.85% versus 46.15%) did not indicate a
statistically significant difference in gender distribution (p-value=0.2734). However, our
patient population with a mean age of almost 66 years did prove it) be a relatively older
population compared with recently reported data, including one that reported an average
age of 46 years for patients with these lesions (which included melanoma in situ and
stage I lesions) (4). One interpretation of this data could suggest that there exists a poor
awareness among the patient population treated in our study about the signs of
melanoma. This data hints at the need for further educational programs about melanoma.
The difference in age between patients with melanoma in situ and stage I melanoma did
not reach statistical significance.

Lesion Characteristics

From our data, stage I melanoma, melanoma in situ, and all lesions considered in
aggregate show a statistically significant (pcO.OOl) predilection to the head and neck
areas, potentially reflecting a referral bias based on expertise. Additionally, when
comparing stage 1 melanoma to melanoma in situ, the former lesions show a propensity
for the trunk (26.76% versus 14.60%). Additionally, the 19 melanoma in situ lesions of
the trunk showed a propensity for the right side (55% on the right versus 20% on the left).
No other significant relationships were observed within the specific side or site of the
body.
The distribution of melanoma in situ lesions in regard to head and neck, trunk,
upper extremity, and lower extremity were fairly consistent with recently published data
(20). Our results suggest a slightly higher preponderance of lesions on the head and neck
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areas (64.23% versus 53.4%) with a smaller percentage of trunk (14.60% versus 20.3%)
and lower extremity (10.95% versus 16.4%) lesions when compared to the previously
mentioned study. These differences did not prove statistically significant.
Unfortunately, due to the significant number of pathological reports that omitted
ulceration and growth phase information, little information can be gleaned from this data
about the stage I melanoma lesions in our study. None of the pathological data indicated
the presence of ulcerations within these lesions. Based on discussions with our
dermatopathologists, we can likely assume that none of these lesions were ulcerated.
This is not an unexpected result as ulceration is often seen in later stages of melanoma
and would warrant further evaluation. Growth phase remains a difficult pathological
criterion to evaluate with recent literature suggesting some inter-observer disagreement
among non-specialist pathologists (26). Interestingly, only two stage I melanoma lesions
in our study were Clark’s level I. A vast majority of the lesions were Clark’s level II.

Overall Recurrence Data

Based on recent published data, our data suggests an extremely low recurrence
rate overall and also when divided between melanoma in situ and stage I melanoma.
Zalaudek, et al. report a 5-year local recurrence rate of 6.8 +/- 1.3% for melanoma in situ
lesions (20). Our data shows a local recurrence rate of 4.38% for melanoma in situ
lesions. Additionally, Ng, et al. reported a 2.58% local recurrence rate for stage I
melanoma. Again, our data demonstrate a 1.41% local recurrence rate for similar lesions.
Our data indicate that all of the local recurrence occurred on the head and neck.
These data prove to be extremely interesting when compared to previous studies.

In one

study of stage I melanoma lesions by Ng, et al. (16), the distribution of sites in which
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recurrences occurred were much more evenly distributed among the head and neck,
trunk, and extremities. In their study, only 26% of the local recurrences occurred on the
head and neck. The significance of the difference in their experience as well as the
ability to extrapolate those data to our experience with melanoma in situ is an area that
requires further analysis.

Predictors of Recurrence

Using data from Table 6, we evaluated the significance of sex, age, body site,
lesion size, and specific diagnosis on recurrence rates. The only factor that proved to be a
statistically significant predictor of recurrence for the lesions in aggregate and also when
evaluated separately by melanoma in situ and stage I melanoma was the location of the
lesion. In aggregate, our analysis suggested that lesions of the head and neck are more
likely to recur (p=0.0186) than lesions elsewhere on the body. This finding is in
agreement with another recent report that also showed that melanoma originating on the
head and neck was a statistically significant predictor of recurrence (20). This implies
the need for caution when removing lesions of the head and neck and interpreting the
pathological specimens. Lesions in patients older than the mean age were 2.5 time more
likely to recur than those in patients younger than the mean age, but this did not prove to
be statistically significant. In a larger cohort of patients, this may prove to be a more
significant predictor of recurrence, although previous reports have shown results similar
to ours (20).
The sex of the patient and the size of the lesions likewise did not show statistical
significance, though based on the odds ratio our data suggests that lesions on female
patients are 1.5 times more likely recur and lesions larger than the mean size are 1.2 times
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more likely to recur. The applicability of this information for all patients with melanoma
in situ or stage I melanoma requires further analysis and future studies in a larger cohort

of patients. The pathological diagnosis of melanoma in situ did not prove to be a
statistically significant predictor of recurrence. This may reflect a more aggressive
surgical treatment of stage I melanoma as compared to melanoma in situ. In our analysis,
we did not evaluate the impact of the depth of invasion of the stage one lesions on
recurrence because only one of the 71 lesions recurred and thus proper statistical analysis
was not possible for this parameter.

Important Treatment considerations

Treatment for each unique case must be tailored to the patient based on the
information the clinician obtains about the lesion. Each instance in which margins less
than generally accepted standards of 5 mm for melanoma in situ and 1 cm for stage I
melanoma was tailored to the specific case. In a number of instances in patients,
especially of advanced age with stage I melanoma, an initial diagnosis of melanoma in
situ was made by biopsy and thus margins less than I cm were indicated for the initial

excision. If pathologic sections of these lesions revealed disease-free margins, close
clinical follow-up was at times deemed the best option for the patient. This was the case
in which a 3 mm margin was used on one patient who. after definitive treatment, was
diagnosed with stage I melanoma. Patients were made aware of the significance of the
diagnosis and importance of close monitoring of the site of involvement. In a number of
these patients, alter being given the option of another stage of excision or monitoring, the
patient chose to monitor closely. Again in these cases, patients were educated about the
risks and benefits of monitoring. The ability to closely monitor the aforementioned
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patients pivots on a clear and strict understanding of disease-free clinical margins
between the surgeon and pathologist.
That being stated, our data suggests that clinical surgical margins narrower than
standard recommended margins of 5 mm clinical margins for melanoma in situ and 1 cm
clinical margins for stage I melanoma may prove to be acceptable on a larger scale. Each
case in our panel of patients in which margins narrower than standard recommended
margins were employed was carefully evaluated.

“ Suboptimally Treated’' Patients: The Impact of Surgical Margins Employed
Differing from other studies (14, 16), our analysis did not suggest a significant
difference of local recurrence rates between those patients treated with currently
recommended clinical surgical margins of 5 mm in melanoma in situ and 1 cm in stage I
melanoma. As discussed previously, various factors led to many cases in which smaller
surgical margins were used. In our patient population, none of the local recurrences
occurred in a patient that was treated with narrower margins than recommended. The six
melanoma in situ lesions that recurred were all treated with 5 mm surgical margins, while
the one stage one melanoma lesion that recurred locally was treated with a 1 cm margin.
Thus, our experience again suggests that under the right circumstances and in specific
situations, narrower surgical margins can be successfully employed for melanoma in situ
and stage I melanoma without compromising disease eradication. Thus, current
recommendations for clinical surgical margins may not need to be strict guidelines. The
current guidelines for margins should remain the goal in each case until further controlled
studies are carried out to evaluate narrow margins. Again, further study is warranted.
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Impact of Number of Stage Employed

As was previously mentioned, all 7 local recurrences occurred in patients who had
been treated with a single stage excision. The clinical significance of this finding is yet
to be determined. To date, we are unaware of other studies that have evaluated the
impact of the number of stages of excision on recurrence. In reviewing the pathology
reports from these recurrences, a number of the reports suggest the presence of tumor
“close to but not on the specimen margin” or some similar statement. In one report, the
tumor was noted to be “greater than 1 mm from the surgical margin.” Although outside
the scope of the study, further investigation into exactly how the specific pathologists use
the term “close” under these circumstances may prove to he useful for future studies.

Predictors of Invasions

From our cohort of patients, we were interested in any clinical or demographic
information that may predict the presence of invasion. From our study, women are no
more likely to have invasive disease. Men and women are equally likely to suffer from
stage I melanoma. Similarly, advanced age as defined by patients older than our mean
population age are not more likely to have stage I melanoma than melanoma in situ.
Therefore, more aggressive lesions such as stage I melanoma in our study are equally
likely to present in younger patients (again defined as patients younger than the average
patient population) and older patients. Likewise, larger lesions were not more likely to be
stage I melanoma than melanoma in situ.
On the other hand, lesions of the head and neck were more likely to be melanoma
in situ lesions than stage I melanoma in a statistically significant fashion (p=0.0033).
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This statistical significance may reflect the impact of sun exposure on the incidence of
early melanoma on the head and neck areas.

Analysis of Trends

To evaluate trends in the diagnosis of these lesions, the number of lesions with a
depth greater than or less than the mean depth at diagnosis of stage I melanoma was first
evaluated over three separate, approximately five year periods. One may hypothesize
that lesions are currently diagnosed at early stages due to better patient and physician
awareness and thus the lesions should show a trend of decreasing depth over these time
periods. Unfortunately, no statistically significant decrease in the depth of lesions was
seen. Conversely, evaluation of these stage I lesions indicated no statistically significant
increase in the depth at diagnosis.
Collectively, these lesions were then evaluated based on trends in diagnosis by
patient sex, the number of patients older than or younger than the mean patient age, and
the number of lesions greater then or less than the mean lesion size. Although combining
stage I melanoma lesions with melanoma in situ lesions may not prove completely
accurate, the idea is to evaluate any potential trends in the diagnosis of the continuum of
early melanoma. Neither patient sex nor lesion size showed any statistically significant
trends. The number of patients older than the mean patient age. however, indicated a
statistically significant (p=0.0271) increase over the three time periods. One of the major
confounding factors in this evaluation is significant increase in the age of the population,
and thus no clear determination about the trend of increasing age in our patient
population can be made without further analysis.
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Summary

Despite a large body of literature about practical consideration in the treatment of
melanoma in situ and stage I melanoma, significant gaps in the understanding of practical
considerations exists. Our study provides a comprehensive analysis of 208 cases and
evaluates the significance of various demographic, pathological and clinical data for these
cases. Findings from our study suggests a need for more studies into the significance of
narrow surgical margins especially in the treatment of melanoma in situ and stage I
melanoma.
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Figure
a

Figure 1: Calculation of Omitted Data:

Representation of our method for calculating missing
lesion size and clinical surgical margin data. To calculate omitted clinical surgical margins length “b” was
subtracted from “a” and divided by 2. To calculated omitted lesion size, the clinical surgical margin was
multiplied by 2 and subtracted from value “b.”
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Tables

Patients Excluded and Exclusion Criteria
Malignant Melanoma, Type

#

Nodular

2

Acral Lentiginous

3

Malignant Melanoma, Superficial Spreading, Depth

1.0 mm - 2,9 mm

10*

Non-Surgical Treatment

Imiquimod
Q-switched ruby laser

10**
4

Other

Patients never cleared of disease pathologically
who were followed clinically
Patient referred for definitive treatment
Consultation only
Local recurrence at presentation
Metastatic disease at presentation
Charts unavailable or incomplete

3
21
2
4
4
14

Table 1: Patients Excluded and Exclusion Criteria: The number of patients and reasons for
exclusion from our study population. *of die 10 patients with thickness >1.0 mm. no recurrences occurred.
**7 of these patients are clinically clear of disease. Abbreviations: mm. millimeters
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MM

% of
MM

MIS

% of
MIS

total

% of
total

HN

31

43.66%

88

64.23%

119

57.21%

UE

8

11.27%

15

10.95%

23

11.06%

T

19

26.76%

20

14.60%

39

18.75%

LE

13

18.31%

14

10.22%

27

12.98%

total

71

100.00%

137

100.00%

208

100.00%

Table 2: Lesion Site by Category: Lesions divided into categories based on diagnosis (melanoma
in situ or stage I melanoma) raid body site. Abbreviations: MM. malignant melanoma (specifically stage I
melanoma in our evaluation); MIS, melanoma in situ; HN. head and neck; UE. upper extremity; T. trunk;
LE, lower extremity

28

Side
Left
Middle
Right
total

MM
28
10
33
71

% of
MM
39.44%
14.08%
46.48%
100.00%

MIS
62
18
57
137

% of
MIS
45.26%
13.14%
41.61%
100.00%

total
90
28
90
208

% of
total
43.27%
13.46%
43.27%
100.00%

Stage 1 Melanoma

HN
UE
1

LE
total

LEFT
13
4
5
6

% of
site
41.94%
50.00%
26.32%
46.15%

28

MIDDLE
4
0
6
0

%
12.90%
0.00%
31.58%
0.00%

RIGHT
14
4
8
7

10

%
45.16%
50.00%
42.11%
53.85%

33

total
31
8
19
13
71

Melanoma in situ
HN
UE
T
LE
total

LEFT
43
8
4

%
48.86%

7
62

50.00%

53.33%
20.00%

MIDDLE
13
0
5
0
18

%
14.77%
0.00%
25.00%
0.00%

RIGHT
32
7
11

Table 3: Lesion Site by Side and Category:

7
57

%
36.36%
46.67%
55.00%
50.00%

88
15
20
14
137

Lesions divided by diagnosis, body site, and
laterality. Abbreviations: MM, malignant melanoma (specifically stage I melanoma in our evaluation);
MIS. melanoma in situ; HN. head and neck; UE. upper extremity; T, trunk; LE. lower extremity.
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Trunk
MIS

% of MIS

MM

% of MM

Back

12

60.00%

Front
Other
total

5

25.00%

3

15.79%

3

15.00%

6

31.58%

10

52.63%

19

20

Head/Neck
MIS

% of MIS

MM

% of MM
35.48%

4.55%

1 1
1

3.41%

5

16.13%

2.27%

2

6.45%

11.36%

3

9.68%

4.55%

1

3.23%

4.55%

1

3.23%

26

29.55%

4

12,90%

4

4.55%

2

6.45%

4

4.55%

1

3.23%

CHEEK
CHIN
EAR
EYELID

27

30.68%

4
3
2

FOREHEAD
LIP
NECK
NOSE
SCALP
TEMPLE
total

10
4
4

88

3.23%

31

Table 4: Site Subsets for Trunk and Head/Neck:

Lesions divided by diagnosis and specific
sites of the trunk and head and neck areas. Abbreviations: MM, malignant melanoma (specifically stage I
melanoma in our evaluation); MIS, melanoma in situ.
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Table 5: Pathological Descriptors of Stage I Melanoma: Stage I melanoma lesions divided
by Clark's level, presence or absence of ulceration, and growth phase. Abbreviations: Y. presence of
ulceration; N. absence of ulceration; NR. no pathological criteria record.
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Out
of

Recurrence

%

Melanoma In situ

6

137

Stage 1 Melanoma

1

71

1.41%

Overall Recurrence

7

208

3.37%

ChiSquared

Odds
Ratio

Fisher's
Exact Test

4.38%

Sex by Recurrence
Female

4

96

44 7%

Male

3

112

2.68%

total

7

208

3.37%

age > mean age

5

117

4.27%

age < mean age

2

91

2.20%

Total

7

208

Head/Neck

7

119

5.88%

Other

0

89

0.00%

1.5808

0.2505

Age by Recurrence

0.2441

2.5962

Body Site by Recurrence

208

Total

0.0186

N/A

Lesion Size by Recurrence
Lesion > mean size

4

86

4.65%

Lesion < mean size

3

122

2.46%

208

total

1.2477

0.7751

Diagnosis by Recurrence
Melanoma in situ

6

137

4.38%

Stage I melanoma

1

71

1.41%

total

Table 6: Recurrence Data:

208

0.1982

0.2695

Recurrence data based on diagnosis, sex, age, body site, and lesion size.
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Melanoma in situ
Clinical
margins
(mm)

total

# of
lesions

Stage I Melanoma

Recurrences

Clinical
margins
(mm)

# of
lesions

Recurrences

2

3

0

3

1

0

3

12

0

5

16

0

4

3

0

7

1

0

5

107

6

8

1

0

7

1

0

10

10

1 1

0

12

47
2

0

137

6

15
20
total

1

1
2

0

71

1

0

Table 7: Clinical Margins: Clinical surgical margins, number of patients in which each margin was
employed, and the number of recurrences based on margins. Abbreviations: mm, millimeters.
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# Stages of Excision

Melanoma
in situ
lesions

# of
recurrences

Stage 1
melanoma
lesions

# of
recurrences

Total
recurrences

1 Stage Excision

112

6

54

1

7

2 Stage Excision

19

0

14

0

0

3 Stage Excision

3

0

3

0

0

4 or greater Stage Excision

3

0

0

0

0

137

6

71

1

7

total

Table 8: Stages of Excisions:
corresponding recurrences.

Number of stages employed for excision based on diagnosis with
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Stage I
melanoma

Out
of

%

Chisq uared

Odds
Ratio

Fisher's
test

Sex by Diagnosis
Female

29

Male

42

total

96

30.21%

112

37.50%

208

0.285

0.74

0.0571

0.5856

0.0033

0.4358

Age by Diagnosis
Age > mean age

32

84

38.10%

Age < mean age

39

124

31.45%

208

total
Body Site by Diagnosis
HN

31

119

26.05%

Other

40

89

44.94%

208

total
Lesion Size by Diagnosis
Lesion > mean size

46

122

37.70%

Lesion < mean size

35

61

57.38%

total

81

183

Table 9: Diagnosis Data:

0.9253

0.1073

Diagnosis of stage I melanoma based on sex, age, body site and lesion size
with corresponding statistical data. The “Out of’ column represents die totally number of melanoma in situ
and stage I melanoma patients within each corresponding category.
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1/90-12/94

1/95-12/00

1/01-2/05

total

Lesion Depth
of Stage I
Melanoma

Depth > mean

11

11

5

27

Depth < mean

17

27

11

55

Total

28

38

16

82

Patient Sex

Female

27

37

32

96

Male

29

46

37

112

Total

56

83

69

208

Age > mean

24

50

43

117

Age < mean

32

33

26

91

total

56

83

69

208

Size > mean

24

36

26

86

Size < mean

32

47

43

122

total

56

83

69

208

Age

Size

Table 10: Trends during three 5 year periods:

Chisquared

0.3647

0.9188

0.0271

0.9442

Data used to evaluate trends in patient mid
lesion characteristics over 15 year time period with corresponding statistical data from the Chi-squared test.
Evaluation of patient sex, age. and lesion size included melanoma in situ ;uul stage I melanoma in
aggregate in an attempt to increase statistical significance. Mean depth of stage 1 melanoma was 0.42
millimeters, mean size was 13.90 millimeters, mid mean age 65.56 years.
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